Blood Res 2016; 51(4):
Published online December 23, 2016
https://doi.org/10.5045/br.2016.51.4.225
© The Korean Society of Hematology
Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Düesseldorf, Germany.
Correspondence to : Correspondence to Thomas Schroeder, M.D., Ph.D. Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Moorenstr. 5, 40225 Düsseldorf, Germany. thomas.schroeder@med.uni-duesseldorf.de
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal myeloid disorders characterized by hematopoietic insufficiency. As MDS and AML are considered to originate from genetic and molecular defects of hematopoietic stem and progenitor cells (HSPC), the main focus of research in this field has focused on the characterization of these cells. Recently, the contribution of BM microenvironment to the pathogenesis of myeloid malignancies, in particular MDS and AML has gained more interest. This is based on a better understanding of its physiological role in the regulation of hematopoiesis. Additionally, it was demonstrated as a ‘proof of principle’ that genetic disruption of cells of the mesenchymal or osteoblastic lineage can induce MDS, MPS or AML in mice. In this review, we summarize the current knowledge about the contribution of the BM microenvironment, in particular mesenchymal stromal cells (MSC) to the pathogenesis of AML and MDS. Furthermore, potential models integrating the BM microenvironment into the pathophysiology of these myeloid disorders are discussed. Finally, strategies to therapeutically exploit this knowledge and to interfere with the crosstalk between clonal hematopoietic cells and altered stem cell niches are introduced.
Keywords Myelodysplastic syndromes, Acute myeloid leukemia, Mesenchymal stromal cells, Hematopoiesis, Niche
Blood Res 2016; 51(4): 225-232
Published online December 23, 2016 https://doi.org/10.5045/br.2016.51.4.225
Copyright © The Korean Society of Hematology.
Thomas Schroeder*, Stefanie Geyh, Ulrich Germing, and Rainer Haas
Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Düesseldorf, Germany.
Correspondence to: Correspondence to Thomas Schroeder, M.D., Ph.D. Department of Hematology, Oncology and Clinical Immunology, University of Duesseldorf, Medical Faculty, Moorenstr. 5, 40225 Düsseldorf, Germany. thomas.schroeder@med.uni-duesseldorf.de
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are clonal myeloid disorders characterized by hematopoietic insufficiency. As MDS and AML are considered to originate from genetic and molecular defects of hematopoietic stem and progenitor cells (HSPC), the main focus of research in this field has focused on the characterization of these cells. Recently, the contribution of BM microenvironment to the pathogenesis of myeloid malignancies, in particular MDS and AML has gained more interest. This is based on a better understanding of its physiological role in the regulation of hematopoiesis. Additionally, it was demonstrated as a ‘proof of principle’ that genetic disruption of cells of the mesenchymal or osteoblastic lineage can induce MDS, MPS or AML in mice. In this review, we summarize the current knowledge about the contribution of the BM microenvironment, in particular mesenchymal stromal cells (MSC) to the pathogenesis of AML and MDS. Furthermore, potential models integrating the BM microenvironment into the pathophysiology of these myeloid disorders are discussed. Finally, strategies to therapeutically exploit this knowledge and to interfere with the crosstalk between clonal hematopoietic cells and altered stem cell niches are introduced.
Keywords: Myelodysplastic syndromes, Acute myeloid leukemia, Mesenchymal stromal cells, Hematopoiesis, Niche
BM microenvironment presenting the HSC niche. The HSC niche is composed mainly of perivascular MSPCs and endothelial cells. They are producing CXCL12 and SCF required for HSC maintenance and retention in BM. BM endothelial cells expressing specific adhesion molecules (e.g. E-selectin) assist homing and engraftment of HSCs. CAR cells regulate both lymphoid progenitor maturation and myeloid progenitor retention. Sympathetic neuronal cells that innervate arterioles regulates HSC mobilization through circadian release of noradrenaline, which modulates CXCL12 expression. ECMs and other cells including macrophage, megakaryocyte, and osteoprogenitor cells are also participating in this landscape. Abbreviations: BM, bone marrow; ECM, extracellular matrix; HSC, hematopoietic stem cell; MSCP, mesenchymal stem and progenitor cell; SCF, stem cell factor; TGF-β1, transforming growth factor beta-1; CAR cell, CXCL12-abundant reticular cells; ECM, extracellular matrix; Nes, nestin; NG2, neuron/glial antigen 2.
Potential pathophysiological models.
Abbreviations: CCL3, Chemokine (C-C motif) ligand 3; ECM, extracellular matrix; G-CSF, Granulocyte-colony stimulating factor; HSC, hematopoietic stem and progenitor cells; MSCP, mesenchymal stem and progenitor cell; ROS, reactive oxygen species; TGF-β, transforming growth factor-beta; TPO, thrombopoietin.
Sahar Jalilivand, Maryam Nabigol, Mehdi Bakhtiyaridovvombaygi and Ahmad Gharehbaghian
Blood Res 2024; 59():Raziyeh Hakak, Behzad Poopak and Ahmad Majd
Blood Res 2024; 59():Hyunwoo Kim, Ja Young Lee, Sinae Yu, Eunkyoung Yoo, Hye Ran Kim, Sang Min Lee and Won Sik Lee
Blood Res 2024; 59():
BM microenvironment presenting the HSC niche. The HSC niche is composed mainly of perivascular MSPCs and endothelial cells. They are producing CXCL12 and SCF required for HSC maintenance and retention in BM. BM endothelial cells expressing specific adhesion molecules (e.g. E-selectin) assist homing and engraftment of HSCs. CAR cells regulate both lymphoid progenitor maturation and myeloid progenitor retention. Sympathetic neuronal cells that innervate arterioles regulates HSC mobilization through circadian release of noradrenaline, which modulates CXCL12 expression. ECMs and other cells including macrophage, megakaryocyte, and osteoprogenitor cells are also participating in this landscape. Abbreviations: BM, bone marrow; ECM, extracellular matrix; HSC, hematopoietic stem cell; MSCP, mesenchymal stem and progenitor cell; SCF, stem cell factor; TGF-β1, transforming growth factor beta-1; CAR cell, CXCL12-abundant reticular cells; ECM, extracellular matrix; Nes, nestin; NG2, neuron/glial antigen 2.
|@|~(^,^)~|@|Potential pathophysiological models.
Abbreviations: CCL3, Chemokine (C-C motif) ligand 3; ECM, extracellular matrix; G-CSF, Granulocyte-colony stimulating factor; HSC, hematopoietic stem and progenitor cells; MSCP, mesenchymal stem and progenitor cell; ROS, reactive oxygen species; TGF-β, transforming growth factor-beta; TPO, thrombopoietin.